Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Jörg Hartmann(University of Tübingen), Hans‐Peter Lipp(Institut de Biologia Evolutiva), Hans‐Georg Kopp(Robert Bosch Hospital), Michael Haap
Cited by 623
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k